TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men, women or diverse~* ≥ 65 years of age~* Patient is mentally and physically able to participate in this study~* Signed informed consent to participate in this study~* Fragile skin condition~* Acute wound (surgical wound or laceration), indicated for treatment with the investigational products for a time period of 7 days~Exclusion Criteria:~* Infection of the target wound~* Alcohol or drug addiction~* Known sensitivity or allergy to any component of the study product~* Patients who participate in any other clinical study investigating drugs or medical devices

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with fragile skin (Type: None): Patient aged 65 years and older presenting with fragile skin and require wound care of an acute wound (laceration or surgical wound). Siliconized sterile wound dressing will be applied for a treatment period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Lipitor on Aortic Stenosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate calcific AS of a tricuspid or bicuspid aortic valve~* Echocardiographic derived mean pressure gradient \>10 mmHg and an aortic valve area of 0.9 to 1.7 cm2 by continuity equation.~* Laboratory evidence of LDL-c\>70 mg/dl within 12 months prior to recruitment.~Exclusion Criteria:~* Left ventricular ejection fraction \<50%~* Valvular area of 0.9 cm2 and a mean gradient \>30 mmHg~* Rheumatic heart disease~* \>Moderate (2+) aortic insufficiency~* Prior statin therapy to include: \>10 mg of atorvastatin (Lipitor) or \>20 mg of other HMG-CoA Reductase Inhibitors (statins)~* End-stage renal disease (ESRD)~* History of thoracic radiation~* Unable or unwilling to sign informed consent~* Unable to unwilling to return for follow-up~* Other clinically important renal, pulmonary, hepatic, neurological, endocrine, or hematological disorders, vasculitis, or any other situation or medical condition that, in the investigator's opinion, would make survival for the duration of the study unlikely, or would otherwise interfere with optimal participation in the study or produce a significant risk to the patient~* Severe pulmonary hypertension (\>55 mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AORTIC STENOSIS PATIENTS (Type: EXPERIMENTAL): Atorvastatin (Lipitor) 40mg by mouth daily is administered to patients with aortic stenosis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of chronic lymphocytic leukemia or~* Diagnosis of non-Hodgkin's lymphoma~* Lymphoplasmacytic lymphoma~* Grade I follicular small cleaved cell lymphoma~* Grade II follicular mixed cell lymphoma~* Diffuse small cleaved cell lymphoma~* Small lymphocytic lymphoma~* Relapsed after at least 1 course of prior therapy~* Availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling donor~* Nonmyeloablative transplantation candidate~* No clinically significant effusions or ascites that would preclude administration of methotrexate~PATIENT CHARACTERISTICS:~-Age: 18 to 75~Performance status:~* Eastern Cooperative Oncology Group (ECOG) 0-2 OR Zubrod 0-2~* Life expectancy: At least 6 months~* Hematopoietic: Not specified~* Hepatic: Bilirubin no greater than 3 mg/dL~* Renal: Creatinine no greater than 2 mg/dL~* Cardiovascular: left ventricular ejection fraction (LVEF) at least 40% on multigated acquisition (MUGA) scan or echocardiogram~* Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) at least 50% of predicted~OTHER:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No uncontrolled bacterial, viral, fungal, or parasitic infection~* Human Immunodeficiency Virus (HIV)1 and Human Immunodeficiency Virus (HIV)2 negative~* No other active malignancy except basal cell skin cancer~* No recent history of drug or alcohol abuse~* No other primary disease or comorbid illness that would severely limit life expectancy~PRIOR CONCURRENT THERAPY~* Biologic therapy:See Disease Characteristics~* Biologic therapy:Prior autologous bone marrow transplantation allowed if disease has progressed after transplantation~* Biologic therapy:No entry on study as part of a tandem autologous transplantation followed by nonmyeloablative allograft protocol~* Chemotherapy: Not specified~* Endocrine therapy: Not specified~* Radiotherapy:Not specified~* Surgery: Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Neurofilaments for NEDA Assessing in MS

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS).~2. Age 18-55 years.~3. EDSS score between 0-5.5.~4. Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit, The Royal London Hospital, Ward 11D~Exclusion Criteria:~1. A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS.~2. Those unable to comply with study requirement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Body Scan Activity on Bone Marrow Transplant Patients and Their Caregivers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntary \& self-selected patients and caregivers~* Located on the leukemia/lymphoma/bone marrow transplant floor at Barnes Jewish Hospital~Exclusion Criteria:~-Patients requiring a language translator or interpreter will be excluded from the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1: Body Scan (Type: EXPERIMENTAL): * The mindfulness-based intervention (MBI) of the Body Scan is expected to take 20 minutes~* Participants will then be guided through the Body Scan. Beginning with awareness of sensations of the left toe, patients will be asked to observe these sensations without judgment, simply noticing and allowing them. Awareness of sensations will continue up through the left leg, then from the right toe up the right leg, then abdomen and chest, then fingertips to arms, then neck, and finally the head. After completing the Body Scan, participants will be given several minutes of quiet to reflect upon how they feel. After opening their eyes, participants will be given the opportunity to discuss and ask questions.~* Caregivers will be encouraged to practice with the patient or on their own, in an additional space on the floor called the Zen Den

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Statins to Reduce D-dimer Levels in Patients With Venous Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a single episode of idiopathic VTE (either DVT or pulmonary embolism) who received at least 6 months of adequate treatment with oral anticoagulants, for whom treatment withdrawal is planned, and with LDL cholesterol levels of equal to or greater than 130 mg/dL.~Exclusion Criteria:~* Age below 18 years,~* Pregnancy or puerperium,~* Active malignancy,~* Need for other anticoagulant treatments (unfractionated heparin, low molecular weight heparin),~* Presence of transient risk factors for VTE \[recent (\< 3 months) surgery,~* Trauma,~* Fractures,~* Acute medical disease with immobilization,~* Pregnancy or use of oral contraceptives\],~* Contraindications to statin therapy,~* Chronic renal failure (defined by creatinine clearance \< 30 mL/min),~* Ongoing treatment with statins or fibrates,~* Major indication to statin therapy \[history of cardiovascular disease, diabetes, elevated cardiovascular risk according to the ATP III criteria(19)\],~* Life expectancy of less than 6 months,~* Geographic inaccessibility,~* Concomitant enrolment in another clinical trial,~* Refused informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Atorvastatin and lipid lowering diet (Type: EXPERIMENTAL): None
- lipid lowering diet (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Growth hormone deficiency as a complication of treatment for pediatric malignancy~* Dexa (bone densitometry)with z-scores of \< -1.0 in at least one site~Exclusion Criteria:~* Dexa (bone densitometry)with z-scores \< -1.0 in at least one site~* Subjects \<18 years old~* Pregnant or lactating patients~* Any contraindication for or unwillingness to consider bisphosphonate treatment~* Inability or unwillingness to undergo bone density evaluation~* Other correctable causes of decreased bone mineral density

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Growth Hormone only (Type: ACTIVE_COMPARATOR): No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
- Growth Hormone & Bisphosphonate Therapy (Type: EXPERIMENTAL): Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Heart Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Heart Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult (\>=18 years of age) heart transplant patients (4-6 weeks post-transplant);~* receipt of first heart (single-organ) transplant;~* standard care regimen of CNI, MMF, and corticosteroids since transplantation.~Exclusion Criteria:~* positive donor-specific cross-match at time of transplantation;~* history of malignancies, other than non-melanoma skin cancer that has been totally excised with no recurrence for 2 years;~* patients participating in another interventional clinical trial or requiring treatment with unmarketed investigational drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: APAD2: Effects of Rehabilitation Programme in Adapted Physical Activity (APA) Among Type 2 Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics~* Age \> 40~* First education in the Education Diabetics Department of the University Hospital Grenoble~* Sedentary patients~* Hemoglobin A1c (HbA1c) \> 7%~* Body mass index (BMI) \> 25~* To be affiliated with disease assurance~* To give written and informed consent~Exclusion Criteria:~* Foot sore \< six months~* Renal disease - proteinuria stage~* Contraindication for exercise~* VO2 max \> 120% Wassermann standard~* Coronary pathology non-stabilization~* Arteriopathy stage 2 non-compensation~* Osteo-articular crippling problem~* Geographically distant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Therapeutic education combining dietary and rehabilitation (Type: EXPERIMENTAL): Therapeutic education combining dietary and rehabilitation (APA)
- Therapeutic education primarily focused on dietary (Type: ACTIVE_COMPARATOR): Therapeutic education primarily focused on dietary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assisted Animal Therapy: ReAnimal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients hospitalized in surgical ICU, not in acute stage of their ICU stay~* adult patient~* able to receive information and to give consent,~* with national social insurance~Exclusion Criteria:~* afraid of animal, dog phobia~* allergic to dog~* immunodepression (neutrophils \<0.5 G/L), induced by treatment (chemotherapy, immunosuppressing treatment with high doses, corticotherapy for more than 2 weeks) or induced by disease (malignant blood disease, AIDS, transplantation, or splenectomy)~* sepsis ongoing~* patient known for having multidrug resistant bacteria~* wounds, or large bandages that could not correctly be covered, including external fixer~* central venous catheter, arterial catheter~* tracheostomy~* agitation, aggressiveness~* pregnant women~* patient deprived of freedom by juridical or administrative decision~* patient under legal protection measure~* patient receiving enforced psychiatric treatment~* patient admitted in a sanitary or social department.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Animal assisted therapy group (Type: EXPERIMENTAL): Patients included in this arm will have animal assisted therapy session in a specific room outside of the ICU. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires
- Control Group (Type: ACTIVE_COMPARATOR): Patients included in this arm will have a sham session : they will leave their hospital bedroom, to go in the AAT session room. There, no specific activity is planned. After 20 minutes, the patient will go back to his room. They will also have blood sampling for multidrug resistant bacteria screening and will answer to questionnaires

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The COVID-19 ICU PRAYER Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female greater than 18 years of age~* Confirmed positive for COVID-19~* Patient admitted to Intensive Care Unit~Exclusion Criteria:~* Patients admitted to ICU for diagnosis that is not COVID-19 positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 110 Years
- Healthy Volunteers: f

Study Arms:
- Prayer (Type: ACTIVE_COMPARATOR): Patients will receive a daily prayer and standard of care treatment from multi-denominational group while in the ICU.
- No Prayer (Type: NO_INTERVENTION): Patients will receive standard of care treatment while in the ICU.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced histologically confirmed well differentiated pancreatic neuroendocrine tumor~* Progressive disease within the last 12 months~* Measurable disease per RECIST Version 1.0 determined by multiphase MRI or triphasic CT~Exclusion Criteria:~* Patients currently requiring somatostatin analog treatment~* Prior therapy with mTOR inhibitors or pasireotide~* Patients with more than 2 prior systemic treatment regimens~* Previous cytotoxic chemotherapy, targeted therapy, somatostatin analogs, or biotherapy within the last 4 weeks~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paseriotide LAR + Everolimus (Type: EXPERIMENTAL): everolimus 10 mg once daily po in combination with pasireotide LAR 60 mg every 28 days (q28d) im
- Everolimus (Type: EXPERIMENTAL): everolimus 10 mg once daily po alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of Stage I, II or III cancer (chemotherapy naïve for breast cancer) with anthracycline-based adjuvant chemotherapy with or without a taxane~* Hemoglobin \>=9 and \<=14 g/dL unrelated to transfusion~* Able to read, understand and complete QoL \& Cognition tools~* Patients with reproductive potential must have a negative serum pregnancy test within 7 days of study enrollment and use an adequate contraceptive method~Exclusion Criteria:~* Patients who will receive more than a total of 24 weeks of chemotherapy~* psychiatric or neurologic condition that would prevent informed consent and completion of questionnaires or that is poorly controlled with the current treatment regimen~* severe hemiparesis or other condition, distal neuropathy, action tremor or other motor dysfunction, visual deficiencies preventing/decrease bimanual keyboard operation~* severe bradyphrenia (slow thinking) or bradykinesia (slow movement)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV RNA \> 15 IU/mL at screening~* HCV genotype 1 or 4~* Chronic HCV infection (≥ 6 months)~* Prior virologic failure after treatment with SOF in combination with simeprevir (SMV) ± RBV or with RBV ± pegylated interferon (PEG)~* Cirrhotic and non-cirrhotic as determined by standard methods~* Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~Key Exclusion Criteria:~* Prior exposure to approved or experimental non-structural protein (NS5A) inhibitors~* Prior exposure to nucleos(t)ide polymerase inhibitors, other than SOF~* Pregnant or nursing female or male with pregnant female partner~* Coinfection with HIV or hepatitis B virus~* Current or prior history of clinical hepatic decompensation~* Hepatocellular carcinoma or other malignancy (with exception of certain resolved skin cancers)~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF 12 weeks, without cirrhosis (Type: EXPERIMENTAL): LDV/SOF for 12 weeks
- LDV/SOF + RBV 12 weeks, without cirrhosis (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks
- LDV/SOF + RBV 12 weeks, with compensated cirrhosis (Type: EXPERIMENTAL): LDV/SOF + RBV for 12 weeks
- LDV/SOF 24 weeks, with compensated cirrhosis (Type: EXPERIMENTAL): LDV/SOF for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility